Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765583 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.
A Phase 4 study of Rhytids, sponsored by Medicis Aesthetics.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT00765583 is a Phase 4 study of Rhytids that has completed, run by Medicis Aesthetics. The registered enrollment target is 75 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00765583, a Phase 4 study of Rhytids, has completed, sponsored by Medicis Aesthetics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
A total of 75 subjects will be enrolled into a 36 month study. Subjects will be treated with Restylane® on both sides of the face (nasolabial folds) at the first visit, on one side of the face at month 4.5 and on the other side of the face at month 9. Both sides of the face will then be treated again at month 18. The subjects will evaluate themselves and will also be evaluated by the treating doctor and a blinded evaluator (a person that does not know when the different sides of the face are treated). Side effects and medications taken during the study will also be recorded.
Conditions Studied
Interventions
- DRUG Restylane
Study Locations (3)
Florida
- Dermatology Research Institute, LLC - Coral Gables
Illinois
- Dayan Facial Plastic Surgery Institute - Chicago
New York
- Rhoda Narins, MD - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765583
The ClinicalTrials.gov registry entry for NCT00765583 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicis Aesthetics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rhytids appearing as the primary indexed condition, and to 1 intervention - of which Restylane is the first listed.
NCT00765583 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00765583 about?
NCT00765583 is a clinical study titled "A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.". A total of 75 subjects will be enrolled into a 36 month study. Subjects will be treated with Restylane® on both sides of the face (nasolabial folds) at the first visit, on one side of the face at month 4.5 and on the other side of the face at month 9. Both sides of the face will then be treated agai...
What is the current status of trial NCT00765583?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2005-11. Estimated completion is 2009-02.
What conditions does trial NCT00765583 study?
This clinical trial studies the following conditions: Rhytids.
What interventions are being tested in trial NCT00765583?
The interventions under investigation include: Restylane (DRUG).
Who is sponsoring clinical trial NCT00765583?
This trial is sponsored by Medicis Aesthetics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00765583 being conducted?
This trial has 3 study locations across Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhytids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.